“…1a is a more potent blocker of sodium currents of frog adult skeletal muscle fibers, 3,4 while 1b is more effective than 1a as an inhibitor of clorgyline-resistant amine oxidase (CRAO) 5 and in the treatment of allodynia. 6 A complex pattern of stereoselectivity in the pharmacokinetics of 1a and 1b in rats and humans has been disclosed by a number of studies revealing differences in the respective areas under the serum concentration-time curve (AUC S , 1a < 1b), 7,8 plasma elimination half-lives (t 1/2 , 1a < 1b), 7,8,9 aliphatic hydroxylation, 10,11 aromatic hydroxylation, 11,12 and conjugation 13,14 (1a being more extensively metabolized than 1b), cumulative urinary excretion (renal clearance of 1a is greater than 1b), 8,9 apparent volumes of distribution (V d , 1a < 1b), 9 and liver uptake (maximum liver concentration of 1b is greater than 1a). 15 The question whether mexiletine enantioselective disposition, which favors the elimination of 1a, may partially compensate the clinical action of the latter remains unanswered.…”